Background & Aims There is controversy regarding the overall value of hepatocellular
carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from …

Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Background There are no systemic treatments for patients with hepatocellular carcinoma
(HCC) whose disease progresses during sorafenib treatment. We aimed to assess the …

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …

Sarcopenia is defined by muscle loss and muscle dysfunction. Sarcopenia is classified into
primary and secondary types, based on the cause. Primary sarcopenia is mainly aging …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …